Roche sues Intas Pharma over patent dispute in India

pharmafile | April 18, 2016 | News story | Medical Communications, Sales and Marketing India, Roche, anaemia, chronic kidney, intas, intas pharmaceuticals, patent 

Roche Pharmaceuticals is suing Indian-based Intas Pharmaceuticals, alleging that the company has infringed upon its patent rights to anaemia drug, Mircera, in the country.

Mircera is an injectable drug used to treat patients with anaemia in chronic-kidney related conditions. It accounts for up to $500 million in global sales for the Swiss pharmaceutical firm.

Speaking to the Economic Times in India, Intas issued a statement claiming that they “also have strong grounds for invalidation of the enforced statement. Intas has launched its own product under the brand name Erypeg at a lower price to Roche’s Mircera, at the same dosage.

This is not the first time that Roche has brought proceedings against Intas in a patent dispute. In 2013, a court ruled in favour of the latter in a dispute related to Roche’s non-small cell lung cancer treatment, Tarceva (erlotinib hydrochloride).

According to the Economics Times, Roche has sought an injunction order against the Erypeg brand, but no decision has yet been taken.

Sean Murray

Related Content


GSK gains positive CHMP opinion for momelotinib for myelofibrosis treatment

GSK has announced that the Committee for Medicinal Products for Human Use (CHMP) of the …

Roche’s Vabysmo approved by FDA for retinal vein occlusion treatment

Roche has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (farcimab) …

Roche announces acquisition of Telavant

Roche has announced that it has entered into a definitive agreement to acquire Telavant Holdings, …

Latest content